

CURRICULUM VITAE

PERSONAL INFORMATION

First name / Surname **Vincenzo Castiglione**
Degree **MD**
Fiscal Code
E-mail
Nationality
Date of birth
Place of birth
Gender

CURRENT POSITION

- **Sant'Anna School of Advanced Studies**, PhD program in Translational Medicine, Pisa, Italy
 - **PhD candidate** - October 2021 to present
 - Project: *Pathophysiology of cardiac damage in amyloidosis* (Advisors: Dr. Giuseppe Vergaro, Prof. Michele Emdin)
 - Representative of PhD students – January 2022 to December 2023
- **Fondazione Toscana Gabriele Monasterio**, Division of Cardiology and Cardiovascular Medicine, Pisa, Italy
 - **Consultant Cardiologist** - November 2022 to present

EDUCATIONAL BACKGROUND

- **University of Pisa**, Pisa, Italy
 - **Cardiology Residency** - November 2018 to October 2022
 - 110/110 *summa cum laude*
Thesis title: *NT-proBNP and High-Sensitivity Troponin T Hold Diagnostic Value in Cardiac Amyloidosis* (Advisors: Dr. Giuseppe Vergaro, Prof. Claudio Passino)
Results presented in a dedicated publication: 10.1002/ejhf.2769.
- **Sant'Anna School of Advanced Studies**, Class of Medical Sciences, Pisa, Italy
 - **Honour Course Student** (Tutor: Prof. Fabio A. Recchia) - September 2011 to December 2018
 - Representative of medical students - December 2013 to October 2015
 - Diploma in Medical Sciences, 100/100 *summa cum laude*
Thesis title: *Interleukin 33/Suppression of Tumorigenicity 2 Pathway in Cardiomyopathies* (Advisors: Dr. Giuseppe Vergaro, Prof. Michele Emdin)
Results presented as Abstract (oral presentation) in an international meeting (ESC HF 2019).
- **University of Pisa**, Faculty of Medicine and Surgery, Pisa, Italy
 - **Medical School** - September 2011 to October 2017
 - MD, 110/110 *summa cum laude*
Thesis title: *Cardioprotective role of sympathetic renal denervation in an*

	<i>experimental model of acute myocardial infarction</i> (Advisor: Prof. Michele Emdin) Results presented as Abstracts in international meetings (ESC 2017, ACC 2018) and in a dedicated publication: 10.1007/s00392-020-01685-y. ▪ Liceo Scientifico “Vincenzo Fardella”, Trapani, Italy - High school - September 2006 to July 2011 - High school diploma, 100/100 <i>summa cum laude</i>
RESEARCH EXPERIENCE	CURRENT ACTIVITY ▪ Fondazione Toscana Gabriele Monasterio, Pisa, Italy Research activity in fields of: 1) clinical assessment and pathophysiology of heart failure and cardiomyopathies; 2) cardiac amyloidosis. Supervisor: Prof. Michele Emdin - 2015 to present PAST EXPERIENCES ▪ Visiting student at National Amyloidosis Centre, University College London, London, UK. Supervisor: Prof. Marianna Fontana - September 2021 ▪ Visiting student at University of California San Francisco, UCSF Medical Center, San Francisco, CA, USA. October to November 2015 ▪ Research internship at Universität Leipzig, Herzzentrum, Leipzig, Germany Research activity in the field of gene therapy in a dog model of dilated cardiomyopathy. Supervisor: Dr. Felix Woitek - October 2014 Results presented as Abstract at the 81st Annual Meeting of the German Cardiac Society ▪ Research internship at Cornell University, Weill Cornell Medicine, Brain and Mind Research Institute, Laboratory of Neurogenetics and Development, New York, NY, USA Research activity in the field of neurogenesis in murine models of mutant cyclin D1 and cyclin D2. Supervisor: Prof. Margaret E. Ross - August to September 2013 ▪ Research internship at National Council of Research, Laboratory of Cardiovascular Pathology, Pisa, Italy Laboratory training in histology and molecular biology using samples from rat models of myocardial infarction. Supervisor: Prof. Fabio A. Recchia - September 2012
LIST OF PUBLICATIONS	Number of publications: 102 Scopus (www.scopus.com/authid/detail.uri?authorId=57200260361): h-index 23, total citations 2097 Researchgate profile: www.researchgate.net/profile/Vincenzo-Castiglione
Indexed articles	1. Capellini K, Gasparotti E, Castiglione V, Palmieri C, Berti S, Rizza A, Celi S.

(*shared co-first)

- Computational Fluid Dynamics-Driven Comparison of Endovascular Treatment Strategies for Penetrating Aortic Ulcer. *J Clin Med*. 2025 Feb 15;14:1290.
2. **Castiglione V**, Montuoro S, Orlando G, Aimo A, Vergaro G, Emdin M. Cardiac amyloidosis: Innovations in diagnosis and treatment. *Eur Heart J Suppl*. 2025 Feb 19;27:i88-i97.
 3. Aimo A, Ferrari Chen YF, **Castiglione V**, Passino C, Genovesi D, Giorgetti A, Emdin M, Vergaro G. Positron emission tomography in cardiac amyloidosis: current evidence and future directions. *Heart Fail Rev*. 2025.
 4. **Castiglione V**, Arzilli C, Ciardetti M, Emdin M, Coceani M. Chest pain after elective percutaneous coronary intervention as trigger of takotsubo syndrome-a case report. *Eur Heart J Case Rep*. 2024.
 5. Magrì D, Ermolaev N, Willixhofer R, Gallo G, Fiori E, Maruotti A, Fantozzi P, **Castiglione V**, Capelle CDJ, Kronberger C, Vergaro G, Passino C, Salvioni E, Del Torto A, Baggiano A, Contini M, Emdin M, Barbato E, Badr Eslam R, Agostoni P. Prevalence and functional impact of chronotropic incompetence in amyloid cardiomyopathy: a multicentre analysis. *Heart*. 2024.
Aimo A, Vergaro G, Panichella G, **Castiglione V**, Emdin M. Transesophageal Echocardiography Before Elective Direct Current Cardioversion in Cardiac Amyloidosis: Too Soon to Discard It? *J Am Coll Cardiol*. 2025;85:e11-e12.
 6. Vergaro G, Aimo A, Genovesi D, Soares Bezerra L, **Castiglione V**, Fabiani I, Barison A, Panichella G, Del Giudice ML, Camerini L, Dugo G, Chubuchna O, Giorgetti A, Buda G, Emdin M. Estimated total amyloid burden from 18F-florbetaben PET predicts all-cause mortality in light-chain cardiac amyloidosis. *Eur Heart J Cardiovasc Imaging*. 2024.
 7. Willixhofer R, Contini M, Emdin M, Magrì D, Bonomi A, Salvioni E, Celeste F, Del Torto A, Passino C, Capelle CDJ, Arzilli C, Fiori E, Capra N, Kronberger C, Ermolaev N, Kammerlander A, Musumeci B, Vergaro G, **Castiglione V**, Rettl R, Tini G, Baggiano A, Fabiani I, Sciomer S, Badr Eslam R, Agostoni P. Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing-A multicentre study. *ESC Heart Fail*. 2024.
 8. Aimo A, Bonino L, **Castiglione V**, Musetti V, Rossetti M, Celi A, Coceani M, Emdin M, Pucci A, Vergaro G. Rarefaction of Blood, But Not Lymphatic Capillaries, in Patients With Cardiac Amyloidosis. *JACC CardioOncol*. 2024;6:797-799.
 9. Alberti M, Biondi F, Barletta V, **Castiglione V**, Bort IR, Del Carlo C, Tavoni A, Grigoratos C, Todiere G, De Caterina R, Aquaro GD. The Great Mimicker Unmasked: A Case Report of Cardiac Sarcoidosis Hidden by Myocardial Infarction and Colon Cancer. *J Cardiovasc Echogr*. 2024;34:144-148.
 10. Gentile F, Giannoni A, Aimo A, **Castiglione V**, Bramanti F, Iudice G, Degl'Innocenti E, Emdin M, Vergaro G, Passino C. Clinical and prognostic significance of central and obstructive apneas in patients with transthyretin cardiac amyloidosis. *Eur J Prev Cardiol*. 2024.
 11. Bonfioli GB, Tomasoni D, Vergaro G, **Castiglione V**, Adamo M, Fabiani I, Loghin V, Lombardi CM, Nicolai A, Metra M, Emdin M, Aimo A. The Mayo ATTR-CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis. *Eur J Heart Fail*. 2024.
 12. Corino C, Aimo A, Luigetti M, Ciccone L, Ferrari Chen YF, Panichella G, Musetti V, **Castiglione V**, Vergaro G, Emdin M, Franzini M. Tetrameric Transthyretin as a Protective Factor Against Alzheimer's Disease. *Mol Neurobiol*. 2024.
 13. Vergaro G, Aimo A, Gentile F, Mandoli GE, Focardi M, **Castiglione V**, Giannoni A, Panichella G, Fornaro A, Carluccio E, Liga R, Salatin M, Passino C, Piepoli MF, Cameli M, Cappelli F, Di Mario C, Emdin M. Eligibility for vericiguat in a

- real-world, contemporary heart failure population. *ESC Heart Fail*. 2024.
14. Morfino P, Aimo A, Giorgetti A, Genovesi D, Merlo M, Limongelli G, **Castiglione V**, Vergaro G, Emdin M. The Role of Scintigraphy with Bone Radiotracers in Cardiac Amyloidosis. *Heart Fail Clin*. 2024;20:307-316.
 15. Morfino P, Aimo A, Franzini M, Vergaro G, **Castiglione V**, Panichella G, Limongelli G, Emdin M. Pathophysiology of Cardiac Amyloidosis. *Heart Fail Clin*. 2024;2:261-270.
 16. Vergaro G, Del Franco A, Carecci A, Ferrari Chen YF, Aimo A, Forini F, Nicolini G, Kusmic C, Faita F, **Castiglione V**, De Tata V, Pucci A, Musetti V, Burchielli S, Passino C, Emdin M. Effects of sacubitril-valsartan on remodelling, fibrosis and mitochondria in a murine model of isoproterenol-induced left ventricular dysfunction. *Int J Cardiol*. 2024.
 17. Emdin M, Aimo A, Vergaro G, **Castiglione V**. Beta-blocking patients with cardiac amyloidosis: Adelante cum juicio. *Int J Cardiol*. 2024.
 18. Rizza A*, **Castiglione V***, Capellini K, Palmieri C, Gasparotti E, Berti S, Celi S. Case Report: Role of numerical simulations in the management of acute aortic syndromes. *Front Cardiovasc Med*. 2024.
 19. Tomasoni D, Aimo A, Porcari A, Bonfioli GB, **Castiglione V**, Saro R, Di Pasquale M, Franzini M, Fabiani I, Lombardi CM, Lupi L, Mazzotta M, Nardi M, Pagnesi M, Panichella G, Rossi M, Vergaro G, Merlo M, Sinagra G, Emdin M, Metra M, Adamo M. Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis. *Eur Heart J Cardiovasc Imaging*. 2024.
 20. Aimo A, Arzilli C, **Castiglione V**, Morfino P, Panichella G, Passino C, Vergaro G, Emdin M. Safety and efficacy of levosimendan in patients with cardiac amyloidosis. *Int J Cardiol*. 2024.
 21. Aimo A, Vergaro G, **Castiglione V**, Fabiani I, Barison A, Gentile F, Ferrari Chen YF, Giorgetti A, Genovesi D, Buda G, Franzini M, Piepoli M, Moscardini S, Rapezzi C, Fontana M, Passino C, Emdin M. Wild-Type Transthyretin Cardiac Amyloidosis is Not Rare in Elderly Subjects: the CATCH Screening Study. *Eur J Prev Cardiol*. 2024.
 22. **Castiglione V**, Aimo A, Vergaro G. Cost-effectiveness of transthyretin cardiac amyloidosis screening and treatment: A Dilemma for the clinician. *Int J Cardiol*. 2024.
 23. Aimo A, Morfino P, Arzilli C, Vergaro G, Spini V, Fabiani I, **Castiglione V**, Rapezzi C, Emdin M. Disease features and management of cardiomyopathies in women. *Heart Fail Rev*. 2024.
 24. Ricci G, Govoni A, Torri F, Astrea G, Buchignani B, Marinella G, Battini R, Manca ML, **Castiglione V**, Giannoni A, Emdin M, Siciliano G. Characterization of Phenotypic Variability in Becker Muscular Dystrophy for Clinical Practice and Towards Trial Readiness: A Two-Years Follow up Study. *J Neuromuscul Dis*. 2024.
 25. **Castiglione V**, Morfino P, Gentile F, Airò E, Passino C, Giannoni A, Emdin M. Apnee ostruttive del sonno e malattie cardiovascolari. *G Ital Cardiol*. 2023.
 26. Aimo A, **Castiglione V**, Fabiani I, Morfino P, Emdin M, Ferrari R, Tavazzi L, Maggioni AP, Rapezzi C. Approccio critico all'interpretazione dei trial cardiovascolari con risultati neutri o negativi. *G Ital Cardiol*. 2023;24:818-826.
 27. Aimo A, Camerini L, Fabiani I, Morfino P, Panichella G, Barison A, Pucci A, **Castiglione V**, Vergaro G, Sinagra G, Emdin M. Valvular heart disease in patients with cardiac amyloidosis. *Heart Fail Rev*. 2023.
 28. Abdeen HA, Helmy ZM, Elnaggar MI, Aldhahi MI, Taha MM, Marques-Sule E, Amin DI, Ibrahim BS, Abdel Aziz A, **Castiglione V**, Atef H. Different Continuous

- Training Intensities Improve Echocardiographic Parameters, Quality of Life, and Functional Capacity in Heart Failure Patients with Reduced Ejection Fraction. *Int J Gen Med*. 2023;16:3933-3945.
29. Aimo A, Teresi L, **Castiglione V**, Picerni AL, Niccolai M, Severino S, Agazio A, Carnevale Baraglia A, Obici L, Palladini G, Ponti L, Argirò A, Cappelli F, Perfetto F, Serenelli M, Trimarchi G, Licordari R, Di Bella G, Chubuchna O, Quattrone F, Nuti S, De Rosis S, Passino C, Rapezzi C, Merlini G, Emdin M, Vergaro G. Patient-reported outcome measures for transthyretin cardiac amyloidosis: the ITALY study. *Amyloid*. 2023;1-10.
 30. Vergaro G, Del Franco A, Aimo A, Gentile F, **Castiglione V**, Saponaro F, Masotti S, Prontera C, Fusari N, Emdin M, Passino C. Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction. *BMC Cardiovasc Disord*. 2023;23:433.
 31. Nicol M, Vergaro G, Damy T, Kharoubi M, Baudet M, Canuti ES, Aimo A, **Castiglione V**, Emdin M, Royer B, Harel S, Cohen-Solal A, Arnulf B, Logeart D. Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study. *Front Cardiovasc Med*. 2023;10:1179968.
 32. Aimo A, Panichella G, Garofalo M, Gasparini S, Arzilli C, **Castiglione V**, Vergaro G, Emdin M, Maffei S. Sex differences in transthyretin cardiac amyloidosis. *Heart Fail Rev*. 2023.
 33. Fabiani I, Pugliese NR, Pedrizzetti G, Tonti G, **Castiglione V**, Chubuchny V, Taddei C, Gimelli A, Del Punta L, Balletti A, Del Franco A, Masi S, Lombardi CM, Cameli M, Emdin M, Giannoni A. Haemodynamic forces predicting remodelling and outcome in patients with heart failure treated with sacubitril/valsartan. *ESC Heart Fail*. 2023.
 34. Morfino P, Aimo A, **Castiglione V**, Chianca M, Vergaro G, Cipolla CM, Fedele A, Emdin M, Fabiani I and Cardinale D. Cardiovascular toxicity from therapies for light chain amyloidosis. *Front Cardiovasc Med*. 2023.
 35. Tomasoni D, Adamo M, Porcari A, Aimo A, Bonfioli GB, **Castiglione V**, Franzini M, Inciardi RM, Khalil A, Lombardi CM, Lupi L, Nardi M, Oriecua C, Pagnesi M, Panichella G, Rossi M, Saccani N, Specchia C, Vergaro G, Merlo M, Sinagra G, Emdin M, Metra M. Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis. *Eur Heart J Cardiovasc Imaging*. 2023.
 36. **Castiglione V**, Gentile F, Vergaro G. Cachexia, sarcopenia and heart failure: A last mile to be walked. *Int J Cardiol*. 2023.
 37. Rapezzi C, Aimo A, Fabiani I, **Castiglione V**, Ferrari R, Maggioni AP, Tavazzi L. Critical Reading of cardiovascular trials with neutral or negative results. *Eur Heart J*. 2023.
 38. Aimo A, Fabiani I, Maccarana A, Vergaro G, Chubuchny V, Pasanisi EM, Petersen C, Poggianti E, Giannoni A, Spini V, Taddei C, **Castiglione V**, Passino C, Fontana M, Emdin M, Venneri L. Valve disease in cardiac amyloidosis: an echocardiographic score. *Int J Cardiovasc Imaging*. 2023.
 39. **Castiglione V**, Gentile F, Ghionzoli N, Chiriaco M, Panichella G, Aimo A, Vergaro G, Giannoni A, Passino C, Emdin M. Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction. *Cardiac Fail Rev*. 2023;9:e09.
 40. **Castiglione V**, Aimo A, Todiere G, Barison A, Fabiani I, Panichella G, Genovesi D, Bonino L, Clemente A, Cademartiri F, Giannoni A, Passino C, Emdin,

- Vergaro G. Role of Imaging in Cardiomyopathies. *Cardiac Fail Rev.* 2023;9:e08.
41. Gentile F, Sciarrone P, Buoncristiani F, **Castiglione V**, Bramanti F, Iudice G, Poletti R, Passino C, Emdin M, Giannoni A. Apnee centrali e malattie cardiovascolari. *G Ital Cardiol.* 2023.
 42. Banydeen R, Eggleston R, Deney A, Monfort A, Ryu JH, Vergaro G, **Castiglione V**, Lairez O, Emdin M, Inamo J, Baqir M, Nevieri R. Risk Stratification in Transthyretin Cardiac Amyloidosis: The Added Value of Lung Spirometry. *J Clin Med.* 2023; 12:3684.
 43. Morfino P, Aimo A, Vergaro G, Sanguinetti C, **Castiglione V**, Franzini M, Perrone MA, Emdin M. Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy. *Pharmaceutics.* 2023;15:1129.
 44. Emdin M, Morfino P, Crosta L, Aimo A, Vergaro G, **Castiglione V**. Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis. *Eur Heart J Suppl.* 2023;25:B79–B84,
 45. Guarnieri E*, **Castiglione V***, De Caterina R. Cardiac Richter's syndrome: a rare case of chronic lymphocytic leukaemia transformation. *Eur Heart J.* 2023.
 46. Aimo A, Tomasoni D, Porcari A, Vergaro G, **Castiglione V**, Passino C, Adamo M, Bellicini MG, Lombardi CM, Nardi M, Palamara G, Varrà GG, Saro R, Allegro V, Merlo M, Sinagra G, Metra M, Emdin M, Rapezzi C. Left ventricular wall thickness and severity of cardiac disease in women and men with transthyretin amyloidosis. *Eur J Heart Fail.* 2023.
 47. Vergaro G*, **Castiglione V***, Aimo A, Prontera C, Masotti S, Musetti V, Nicol M, Cohen-Solal A, Logeart D, Georgiopoulos G, Chubuchny V, Giannoni A, Clerico A, Buda G, Patel KN, Razvi Y, Patel R, Wechalekar A, Lachmann H, Hawkins PN, Passino C, Gillmore J, Emdin M, Fontana M. NT-proBNP and High-Sensitivity Troponin T Hold Diagnostic Value in Cardiac Amyloidosis. *Eur J Heart Fail.* 2023.
 48. Morfino P, Aimo A, **Castiglione V**, Emdin M. Trattamento della fibrosi cardiaca: dagli antagonisti neuro-ormonali alle cellule CAR-T. *G Ital Cardiol.* 2023.
 49. Musetti V, Greco F, **Castiglione V**, Aimo A, Palmieri C, Genovesi D, Giorgetti A, Emdin M, Vergaro G, McDonnell LA, Pucci A. Tissue Characterization in Cardiac Amyloidosis. *Biomedicines.* 2022;10:3054.
 50. Ghio S, Acquaro M, Agostoni P, Ambrosio G, Carluccio E, **Castiglione V**, Colombo D, D'Alto M, Delle Grottaglie S, Dini FL, Emdin M, Fortunato M, Guaricci AI, Jacoangeli F, Marra AM, Paolillo S, Papa S, Scajola LV, Correale M, Palazzuoli A. Right heart failure in left heart disease: imaging, functional, and biochemical aspects of right ventricular dysfunction. *Heart Fail Rev.* 2022.
 51. Morfino P, Aimo A, **Castiglione V**, Gálvez-Montón C, Emdin M, Bayes-Genis A. Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy. *Heart Fail Rev.* 2022.
 52. Rossi A, Giannoni A, Nesti M, Notarstefano P, **Castiglione V**, Solarino G, Teresi L, Mirizzi G, Russo V, Panchetti L, Startari U, Ripoli A, Gentile F, Santoro A, Botto N, Casolo G, Sieira J, Pieroni M, Santangeli P, Emdin M, Piacenti M. Prognostic value of right ventricular refractory period heterogeneity in Type-1

Brugada electrocardiographic pattern. *Europace*. 2022.

53. Bayes-Genis A, Aimo A, Jhund P, Richards AM, de Boer RA, Arfsten H, Fabiani I, Lupón J, Anker SD, González A, **Castiglione V**, Metra M, Mueller C, Núñez J, Rossignol P, Barison A, Butler J, Teerlink J, Filippatos G, Ponikowski P, Vergaro G, Zannad F, Seferovic P, Rosano G, Coats AJ, Emdin M, Januzzi JL. A review from the Biomarkers Working Group of the Heart Failure Association of the ESC: A review from the Biomarkers Working Group of the Heart Failure Association of the ESC. *Eur J Heart Fail*. 2022.
54. Sanguinetti C, Minniti M, Susini V, Caponi L, Panichella G, **Castiglione V**, Aimo A, Emdin M, Vergaro G, Franzini M. The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism. *Biomedicines*. 2022;10:1906.
55. Morfino P, Aimo A, **Castiglione V**, Vergaro G, Emdin M, Clerico A. Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond. *J Cardiovasc Dev Dis*. 2022
56. Chianca M, Fabiani I, Del Franco A, Grigoratos C, Aimo A, Panichella G, Giannoni A, **Castiglione V**, Gentile F, Passino C, Cipolla CM, Cardinale DM, Emdin M. Management and treatment of cardiotoxicity due to anticancer drugs: 10 questions and answers. *Eur J Prev Cardiol*. 2022.
57. Vergaro G, Aimo A, Rapezzi C, **Castiglione V**, Fabiani I, Pucci A, Buda G, Passino C, Lupón J, Bayes-Genis A, Emdin M, Braunwald E. Atrial amyloidosis: mechanisms and clinical manifestations. *Eur J Heart Fail*. 2022.
58. Baronti A, Gentile F, Manetti AC, Scatena A, Pellegrini S, Pucci A, Franzini M, **Castiglione V**, Maiese A, Giannoni A, Pistello M, Emdin M, Aquaro GD, Di Paolo M. Myocardial Infarction Following COVID-19 Vaccine Administration: Post Hoc, Ergo Propter Hoc? *Viruses*. 2022; 14:1644.
59. Chianca M, Panichella G, Fabiani I, Giannoni A, L'Abbate S, Aimo A, Del Franco A, Vergaro G, Grigoratos C, **Castiglione V**, Cipolla CM, Fedele A, Passino C, Emdin M, Cardinale DM. Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers. *Front Cardiovasc Med*. 2022;9:936654.
60. Quattrone F, Aimo A, **Castiglione V**, Passino C, Bergamasco M, Barsanti S, Nuti S, Emdin M. Using co-creation to develop a cardiology online open course: an effective approach for implementing digital learning. *J Cardiovasc Med*. 2022.
61. Aimo A, **Castiglione V**, Bayes-Genis A. Do we need to EVALUATE multiple biomarkers and/or the same biomarkers multiple times in patients with HF? *Eur J Heart Fail*. 2022.
62. Vergaro G, Aimo A, **Castiglione V**, Emdin M. Stroke in ATTR cardiac amyloidosis: does rhythm only matter? *Int J Cardiol*. 2022;363:127-128.
63. Bayés-Genís A, Aimo A, Metra M, Anker S, Seferovic P, Rapezzi C, **Castiglione V**, Núñez J, Emdin M, Rosano G, Coats AJ. Head-to-head comparison between recommendations by the ESC and ACC/AHA/HFSA Heart Failure Guidelines. *Eur J Heart Fail*. 2022.
64. Emdin M, Aimo A, **Castiglione V**. Is Targeting Cyclic Guanosine Monophosphate by Vericiguat Effective to Treat Ischaemic Heart Failure with Reduced Ejection Fraction? Yes, It Is. *Eur J Heart Fail*. 2022.
65. **Castiglione V**, Vergaro G, Emdin M. Targeting precipitants to prevent heart

failure hospitalization. Does season matter? *Int J Cardiol.* 2022.

66. Aimo A, **Castiglione V**, Rapezzi C, Franzini M, Panichella G, Vergaro G, Gillmore J, Fontana M, Passino C, Emdin M. RNA-targeting and gene editing therapies for transthyretin amyloidosis. *Nat Rev Cardiol.* 2022;19:655-667.
67. Aimo A, Fabiani I, Giannoni A, Mandoli GE, Pastore MC, Vergaro G, Spini V, Chubuchny V, Pasanisi EM, Petersen C, Poggianti E, Taddei C, **Castiglione V**, Latrofa S, Panichella G, Sciacaluga C, Georgiopoulos G, Passino C, Cameli M, Emdin M. Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis. *Eur Heart J Cardiovasc Imaging.* 2022.
68. Gentile F, **Castiglione V**, De Caterina R. Coronary Artery Anomalies. *Circulation.* 2021;144:983-996.
69. Aimo A, **Castiglione V**, Barison A, Chubuchnyi V, Emdin M. The Left Ventricular Mass-to-Strain Ratio: Enough to Differentiate ATTR From AL Cardiac Amyloidosis? *JACC Cardiovasc Imaging.* 2021;14:1877-1878.
70. **Castiglione V**, Modena M, Aimo A, Chiti E, Botto N, Vittorini S, Guidi B, Vergaro G, Barison A, Rossi A, Passino C, Giannoni A, Di Paolo M, Emdin M. Molecular Autopsy of Sudden Cardiac Death in the Genomics Era. *Diagnostics.* 2021;11:1378.
71. Vergaro G, Aimo A, Campora A, **Castiglione V**, Prontera C, Masotti S, Musetti V, Chianca M, Valleggi A, Spini V, Emdin M, Passino C. Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure. *Amyloid.* 2021;28:252-258.
72. Aimo A, **Castiglione V**, Vergaro G, Panichella G, Senni M, Lombardi CM, Emdin M. The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction. *Heart Fail Rev.* 2021
73. Ghionzoli N, Gentile F, Del Franco AM, **Castiglione V**, Aimo A, Giannoni A, Burchielli S, Cameli M, Emdin M, Vergaro G. Current and emerging drug targets in heart failure treatment. *Heart Fail Rev.* 2021.
74. Aimo A, Rapezzi C, Perfetto F, Cappelli F, Palladini G, Obici L, Merlini G, Di Bella G, Serenelli M, Zampieri M, Milani P, Licordari R, Teresi L, Ribarich N, **Castiglione V**, Quattrone F, De Rosis S, Vergaro G, Panichella G, Emdin M, Passino C. Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis. *Eur J Clin Invest.* 2021;12:e13598.
75. **Castiglione V**, Aimo A, Vergaro G, Saccaro L, Passino C, Emdin M. Biomarkers for the diagnosis and management of heart failure. *Heart Fail Rev.* 2021.
76. Vergaro G, **Castiglione V**, Aimo A, Prontera C, Musetti V, Masotti S, Giannelli E, Maltinti M, Passino C, Emdin M. Biomarcatori per la diagnosi e la gestione dello scompenso cardiaco: nuove frontiere. *G Ital Cardiol.* 2021;22:386-396.
77. **Castiglione V**, Vergaro G, Aimo A, Prontera C, Musetti V, Masotti S, Battaglia D, Di Cecco P, Emdin M, Passino C. Biomarcatori per la diagnosi e la gestione dello scompenso cardiaco: i peptidi natriuretici. *G Ital Cardiol.* 2021;22:292-300.
78. Vergaro G, **Castiglione V**, Poletti R, Buda G, Pucci A, Musetti V, Genovesi D, Aimo A, Passino C, Emdin M. Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient. *JACC Case Rep.* 2021;3:450-4.

79. **Castiglione V**, Franzini M, Aimo A, Carecci A, Lombardi CM, Passino C, Rapezzi C, Emdin M, Vergaro G. Use of biomarkers to diagnose and manage cardiac amyloidosis. *Eur J Heart Fail*. 2021;23:217-230.
80. Fabiani I, Aimo A, Grigoratos C, **Castiglione V**, Gentile F, Saccaro LF, Arzilli C, Cardinale D, Passino C, Emdin M. Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets. *Heart Fail Rev*. 2020.
81. Aimo A, Chubuchny V, Vergaro G, Barison A, Nicol M, Cohen-Solal A, **Castiglione V**, Spini V, Giannoni A, Petersen C, Taddei C, Pasanisi E, Chacko L, Martone R, Knight D, Brown J, Martinez-Naharro A, Passino C, Fontana M, Emdin M. A simple echocardiographic score to rule out cardiac amyloidosis. *Eur J Clin Invest*. 2020;13:e13449.
82. Aimo A, Di Paolo M, **Castiglione V**, Modena M, Barison A, Benvenuti M, Bugelli V, Campobasso CP, Guidi B, Camici PG, Emdin M. Scared to Death: Emotional Stress Causing Fatal Myocardial Infarction With Nonobstructed Coronary Arteries in Women. *JACC Case Rep*. 2020.
83. Emdin M, Aimo A, **Castiglione V**, Vergaro G, Georgiopoulos G, Saccaro LF, Lombardi CM, Passino C, Cerbai E, Metra M, Senni M. Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure. *J Am Coll Cardiol*. 2020;76:1795-1807.
84. Castaldo N, Aimo A, **Castiglione V**, Padalino C, Emdin M, Tascini C. Safety and Efficacy of Amiodarone in a Patient With COVID-19. *JACC Case Rep*. 2020;2:1307-1310.
85. Pastormerlo LE, Burchielli S, Ciardetti M, Aquaro GD, Grigoratos C, **Castiglione V**, Pucci A, Franzini M, Giorgetti A, Marzullo P, Benelli E, Masotti S, Musetti V, Bernini F, Berti S, Passino C, Emdin M. Myocardial salvage is increased after sympathetic renal denervation in a pig model of acute infarction. *Clin Res Cardiol*. 2020.
86. Aimo A, Vergaro G, **Castiglione V**, Rapezzi C, Emdin M. Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis. *Eur J Intern Med*. 2020;80:66-72.
87. Grigoratos C, Aimo A, Barison A, **Castiglione V**, Todiere G, Ricci G, Siciliano G, Emdin M. Cardiac magnetic resonance in patients with muscular dystrophies. *Eur J Prev Cardiol*. 2020.
88. Barison A, Aimo A, **Castiglione V**, Arzilli C, Lupón J, Codina P, Santiago-Vacas E, Cediel G, Emdin M, Bayes-Genis A. Cardiovascular disease and COVID-19: les liaisons dangereuses. *Eur J Prev Cardiol*. 2020;27:1017-1025.
89. Aimo A, **Castiglione V**, Lombardi CM. Effects of vericiguat in heart failure with reduced ejection fraction: do not forget sST2. *Eur J Heart Fail*. 2020.
90. Aimo A, Barison A, **Castiglione V**, Emdin M. The unbearable underreporting of comorbidities in heart failure clinical trials. *Eur J Heart Fail*. 2020;22:1043-1044.
91. **Castiglione V**, Chiriaco M, Emdin M, Taddei S, Vergaro G. Statin therapy in COVID-19 infection. *Eur Heart J Cardiovasc Pharmacother*. 2020;6:258-259.
92. Modena M, **Castiglione V**, Aretini P, Mazzanti CM, Chiti E, Giannoni A, Emdin M, Di Paolo M. Unveiling a sudden unexplained death case by whole exome

sequencing and bioinformatic analysis. *Mol Genet Genomic Med.* 2020;8:e1182.

93. Barison A, Aimo A, Mirizzi G, **Castiglione V**, Ripoli A, Panchetti L, Rossi A, Giannoni A, Startari U, Aquaro GD, Emdin M, Piacenti M. The extent and location of late gadolinium enhancement predict defibrillator shock and cardiac mortality in patients with non-ischaemic dilated cardiomyopathy. *Int J Cardiol.* 2020;307:180-186.
94. **Castiglione V**, Aimo A, Murzi B, Pucci A, Aquaro GD, Barison A, Clemente A, Spini V, Benedetti G, Emdin M. What Is Hidden Behind Inferior Negative T Waves: Multiple Cardiac Glomangiomas. *JACC Case Rep.* 2019;1:657-662.
95. Boldrini M, Cappelli F, Chacko L, Restrepo-Cordoba MA, Lopez-Sainz A, Giannoni A, Aimo A, Baggiano A, Martinez-Naharro A, Whelan C, Quarta C, Passino C, **Castiglione V**, Chubuchny V, Spini V, Taddei C, Vergaro G, Petrie A, Ruiz-Guerrero L, Moñivas V, Mingo-Santos S, Mirelis JG, Dominguez F, Gonzalez-Lopez E, Perlino S, Pontone G, Gillmore J, Hawkins PN, Garcia-Pavia P, Emdin M, Fontana M. Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis. *JACC Cardiovasc Imaging.* 2019;13:909-920.
96. Aimo A, **Castiglione V**, Borrelli C, Saccaro LF, Franzini M, Masi S, Emdin M, Giannoni A. Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies. *Eur J Prev Cardiol.* 2019;27:494-510.
97. Aimo A, Maisel AS, **Castiglione V**, Emdin M. sST2 for Outcome Prediction in Acute Heart Failure: Which Is the Best Cutoff? *J Am Coll Cardiol.* 2019;74:478-479.
98. Emdin M, Aimo A, Rapezzi C, Fontana M, Perfetto F, Seferović PM, Barison A, **Castiglione V**, Vergaro G, Giannoni A, Passino C, Merlini G. Treatment of cardiac transthyretin amyloidosis: an update. *Eur Heart J.* 2019;40:3699-3706.
99. Barbiero S, Aimo A, **Castiglione V**, Giannoni A, Vergaro G, Passino C, Emdin M. Healthy hearts at hectic pace: From daily life stress to abnormal cardiomyocyte function and arrhythmias. *Eur J Prev Cardiol.* 2018;25:1419-1430.
100. Aimo A, Giannoni A, **Castiglione V**, Mancuso M, Siciliano G, Piepoli MF, Passino C, Emdin M. Neurohormonal modulation for treatment of cardiac involvement in dystrophinopathies and mitochondrial disease. *Eur J Prev Cardiol.* 2017;24:1718-1724.
101. Aimo A, Vergaro G, **Castiglione V**, Barison A, Pasanisi E, Petersen C, Chubuchny V, Giannoni A, Poletti R, Maffei S, Januzzi JL Jr, Passino C, Emdin M. Effect of sex on reverse remodeling in chronic systolic heart failure. *JACC Heart Fail.* 2017;5:735-742.

Book chapters

1. **Castiglione V**, Franzini M, Masotti S, Arzilli C, Emdin M, Vergaro G. Biomarkers: Monoclonal Protein and Indicators of Cardiac Damage. In: *Cardiac Amyloidosis*. Springer, Cham, 2024.
2. Franzini M, Sanguinetti C, Musetti V, **Castiglione V**, Aimo A, Emdin M, Vergaro G, Emdin M. Plasma Transthyretin and Its Ligands. In: *Cardiac Amyloidosis*. Springer, Cham, 2024.
3. **Castiglione V**, Gentile F, Aimo A, Emdin M. Left Ventricular Diastolic

	Dysfunction. In: <i>Hypertension and Heart Failure. Updates in Hypertension and Cardiovascular Protection</i>. Springer, Cham, 2023. - Emdin M, Bedeir N, Manzato E, Poletti R, Aimo A, Chiriaco M, Castiglione V. Fisiopatologia e nosografia generale delle amiloidosi. In: <i>Amiloidosi. Come si diagnostica, come si cura</i>. Sant'Anna Medical Reviews, Pisa University Press, Pisa, 2020; p.35-48. Castiglione V, Caponi L, Zucchinetti C, Paolicchi A, Franzini M, Vergaro G. Biomarcatori: strumenti per screening, diagnosi, prognosi e guida al trattamento. In: <i>Amiloidosi. Come si diagnostica, come si cura</i>. Sant'Anna Medical Reviews, Pisa University Press, Pisa, 2020; p.87-110. Castiglione V, Franzini M, Chiriaco M, Vergaro G. Indagini proteomiche nella diagnosi e caratterizzazione dell'amiloidosi. In: <i>Amiloidosi. Come si diagnostica, come si cura</i>. Sant'Anna Medical Reviews, Pisa University Press, Pisa, 2020; p.169-182. - Poletti R, Aimo A, Castiglione V, Di Gangi A, Iudice G, Micalizzi M, Passino C, Emdin M. Diagnostic Tools: The Easier, the Better. In: <i>The Breathless Heart</i>. Springer, Cham, 2017; p.219-234. - Bertone C, Biavati L, Borrelli C, Castiglione V, Chiriaco M, Di Gangi A, Germani MM, Meola L, Taddei E, Testa D. La valutazione dell'assistenza nell'esperienza degli ospedali della University of California – San Francisco. In: <i>La valutazione della performance delle Aziende Ospedaliero-Universitarie</i>. Il Mulino, Bologna, 2016; p.121-134.
Other publications	- Camerini L, Aimo A, Pucci A, Castiglione V, Musetti V, Masotti S, Caponi L, Vergaro G, Passino C, Clerico A, Franzini M, Emdin M. Serum and tissue light-chains as disease biomarkers and targets for treatment in AL amyloidosis. <i>Vessel Plus</i>. 2022;6:59. Castiglione V, Pavan I. Naftoli Emdin. Il Dottore russo. In: <i>Vite sospese. 1938. Università ed ebrei a Pisa</i>. Pisa University Press, Pisa, 2020; p.177-186. - Vergaro G, Borrelli C, Castiglione V, Fatini C, Sticchi E, Del Franco A, Battaglia D, Passino C, Prontera C, Emdin M. Biomarcatori del sistema renina-angiotensina-aldosterone nello scompenso cardiaco: quale impatto clinico? <i>Ligand Assay</i>. 2015;20.
ABSTRACTS	Author and co-author of over 30 abstracts presented at national and international meetings.
TEACHING EXPERIENCE (university courses, masters)	2024 “Masterclass - Cardiomiopatie a fenotipo ipertrofico”. FTGM, Pisa - 02-03/12/2024. Lecture: “Biomarcatori, dalla diagnosi alla prognosi” - Corso di Alta Formazione “Fisiopatologia, Clinica e Terapia dell’Amiloidosi Cardiaca”. FTGM, Pisa - October 2024. Lecture: “Utilizzo dei biomarcatori nell’amiloidosi cardiaca”; “Discussione casi clinici” - Il level master course on “Pathophysiology and management of heart failure”. Sant’Anna School of Advanced Studies, Pisa - 16-17/09/2024. Lecture: “CardioPulmonary Exercise Test: Practical Session” 2023 “Cardiac Amyloidosis MasterClass”. FTGM, Pisa - 27-28/11/2023. Lecture: “Clinical cases”

	- Il level master course on “Pathophysiology and management of heart failure”. Sant’Anna School of Advanced Studies, Pisa - 19/04/2023 and 21/11/2023. Lecture: <i>“Biomarkers: inflammation, fibrosis & more”</i>; <i>“Amyloidosis - biomarkers & echo”</i>; <i>“Novel interventional approaches in chronic HF”</i> 2022 “Cardiac Amyloidosis MasterClass”. FTGM, Pisa - 06-06/12/2022 and 04-05/07/2022. Lecture: <i>“Clinical cases”</i> - Il level master course on “Pathophysiology and management of heart failure”. Sant’Anna School of Advanced Studies, Pisa - 04/04/2022. Lecture: <i>“Comparison between the Recommendations by the 2021 ESC and the 2022 ACC/AHA/HFSA Heart Failure Guidelines”</i> 2021 - Il level master course on “Pathophysiology and management of heart failure”. Sant’Anna School of Advanced Studies, Pisa - 05-09/07/2021. Lectures: <i>“Biomarkers: inflammation & fibrosis”</i>; <i>“Biomarkers in amyloidosis”</i> 2019 - Il level master course on “Pathophysiology and management of heart failure”. Sant’Anna School of Advanced Studies, Pisa - 11-15/11/2019. Lectures: <i>“Addressing arrhythmias and ischemia in acute heart failure”</i>; <i>“Clinical case: a legless heart”</i>
INVITED LECTURER (symposiums, conferences, webinars)	2024 - Training course for nurses. <i>“Management del paziente con scompenso cardiaco avanzato: una gestione multidisciplinare”</i>. FTGM, Pisa - 09-10/12/2024. Speaker - Symposium “Ruolo dei marcatori cardiaci nella prevenzione, diagnosi e follow-up delle malattie cardiovascolari”. Pisa – 06/12/2024. Speaker: <i>“Scompenso cardiaco e Amiloidosi cardiaca”</i> - Masterclass Amiloidosi Cardiaca. Palermo - 16/11/2024. Speaker: <i>“Il trattamento specifico della amiloidosi cardiaca ATTR”</i> - Symposium <i>“Proteomics in cardiac amyloidosis European and American perspectives”</i>. SSSUP, Pisa - 08/11/2024. Moderator. - Regional Congress of the Società Italiana di Cardiologia. Siena - 29/09/2024. Speaker: <i>“Heart Failure & Atrial Fibrillation: A Dangerous Crossroad”</i> - Regional Congress of the Associazione Nazionale Medici Cardiologi Ospedalieri. Pisa - 27/09/2024. Speaker: <i>“Burden di FA e terapia anticoagulante: abbiamo bisogno di un valore soglia?”</i> - Training course for nurses. <i>“Iter diagnostico - terapeutico dell'amiloidosi cardiaca”</i>. FTGM, Pisa - 20/05/2024 and 24/05/2024. Speaker. - Symposium “How to... in HF”. FTGM, Pisa - 04-05/12/2023. Speaker: <i>“Peptidi natriuretici in ospedale e in primary care: diagnosi, prognosi e cos’altro?”</i>; <i>“Altri biomarkers di cui non si può fare a meno: le troponine (solo loro?)”</i> 2023 - Training course for nurses. <i>“Management del paziente con scompenso cardiaco avanzato: una gestione multidisciplinare”</i>. FTGM, Pisa - 04-05/12/2023. Speaker. - Regional Congress of the Società Italiana di Cardiologia. Florence - 20/10/2023.

Speaker.

- Regional Congress of the Associazione Nazionale Medici Cardiologi Ospedalieri. Florence - 29-30/09/2023. **Speaker:** *"Terapia ablativa della fibrillazione atriale: Quasi sempre vs Quasi mai"*
- Symposium "Medicina cardiovascolare 2023". Fondazione Pisana per la Scienza ONLUS, Pisa - 15-16/09/2023. **Discussant and Speaker:** *"Oltre il farmaco: device nello scompenso"*
- Training course for nurses. *"Iter diagnostico - terapeutico dell'amiloidosi cardiaca"*. FTGM, Pisa - 15-16/05/2023. **Speaker.**
- Symposium "Imaging cardiaco e Trattamento delle patologie cardiovascolari - Progressi in Ecocardiografia 2023". Pisa - 31/03/2023. **Speaker:** *"Work-up diagnostico nelle amiloidosi cardiache: cosa fare e cosa non dimenticare"*

2022

- Virtual Conference "Biomarkers of the Future 2022". 15-16/11/2022. **Speaker** (session "Young researchers competition - part III: cardio, renal & more"): *"NT-proBNP and High-Sensitivity Troponin T Hold Diagnostic Value in Cardiac Amyloidosis"*
- Webinar "La gestione pratica del paziente scompensato". 10/11/22. **Speaker:** *"Un caso di paziente con scompenso e diabete, come gestire le terapie?"*
- Symposium "Pisa Amyloid 2022". FTGM, Pisa - 30/06/2022 and 01/07/2022. **Member of the Scientific Committee and Speaker:** *"Biomarkers to diagnose and stage cardiac amyloidosis"*
- Symposium "Heart Failure 2022 - Question Time". Fondazione Pisana per la Scienza ONLUS, Pisa - 10/06/2022. **Member of the Scientific Committee and Speaker:** *"Scompenso cardiaco non ischemico: what's behind?"*
- "XXIV Corso di Aggiornamento - Terapie antitrombotiche in cardiologia". Florence - 06-07/05/2022. **Discussant**
- "Pisa Amyloid Webinar". Pisa University Press, Pisa - February 2022. **Speaker:** *"Role of echocardiography in the diagnosis of cardiac amyloidosis"; "A patient with heart failure with preserved ejection fraction"; "A patient with acute dyspnoea and elevated natriuretic peptides"*
- Symposium "Medicina cardiovascolare 2022". Fondazione Pisana per la Scienza ONLUS, Pisa - 28-29/01/2022. **Discussant and Speaker:** *"Cardiac Amyloidosis"*

2021

- Symposium "Hot Topics in Cardiovascular Medicine VII - Aggiornamenti sulle dislipidemie". Pisa - 24/05/2021 and 26/05/2021. **Discussant**

2020

- 81st National Congress of the Italian Society of Cardiology. Rome - 17-20/12/2020. **Speaker:** *"Red flags nella diagnosi di amiloidosi cardiaca: un caso clinico"*

2019

- 5th edition workshop "La Fondazione Toscana Gabriele Monasterio per la salute di genere". FTGM, Pisa - 04/12/2019. **Speaker:** *"Tales of frail coronary arteries: spontaneous coronary artery dissection"*
- 11th ARCA Imaging "L'imaging clinico delle cardiomiopatie". Matera - 13-14/09/2019. **Speaker:** *"Manifestazioni cardiache nelle miopatie mitocondriali: cambia la prognosi del paziente?"*

	2017 ▪ 3rd edition workshop “La Fondazione Toscana Gabriele Monasterio per la salute di genere”. FTGM, Pisa - 22/11/2017. Speaker: “<i>Biomarcatori cardiovascolari e differenze di genere</i>” ▪ Symposium “Le scuole di eccellenza si raccontano. L’avventura della conoscenza e della scoperta nell’universo delle scienze pure e applicate”. Senate of the Republic, Rome - 13/04/2017. Speaker: “<i>E-schoolapius: l’e-learning per i medici di domani</i>”
EDITOR ACTIVITY	▪ International Journal of Cardiology (IF: 4.04): Editorial Board ▪ Frontiers in Cardiovascular Medicine (IF: 5.85): Review Editor ▪ European Heart Journal - Case Reports: Senior Reviewer ▪ Cardiology and Therapy: Advisory Board
REVIEWER ACTIVITY	WoS profile: https://www.webofscience.com/wos/author/record/AAB-3483-2020 Reviewer for (2022 Impact Factor): European Heart Journal (IF: 35.86); European Journal of Heart Failure (IF: 17.35); JACC-Heart Failure (IF: 12.54); Cardiovascular Diabetology (IF: 8.95); European Journal of Preventive Cardiology (IF: 8.53); Clinical Chemistry and Laboratory Medicine (IF: 8.49); European Heart Journal - Quality of Care and Clinical Outcomes (IF: 7.06); Frontiers in Cardiovascular Medicine (IF: 5.85); Annals of Medicine (IF: 5.35); Journal of Cellular and Molecular Medicine (IF: 5.31); Scientific reports (IF: 5.00); Journal of Clinical Medicine (IF: 4.96); Biomedicines (IF: 4.76); Journal of Cardiovascular Development and Disease (IF: 4.42); International Journal of Cardiology (IF: 4.04); Diagnostics (IF: 3.99); Heliyon (IF: 3.78); PLOS One (IF: 3.75); ESC Heart Failure (IF: 3.61); Journal of Personalized Medicine (IF: 3.51); Molecular Genetics & Genomic Medicine (IF: 2.47); Journal of Cardiovascular Medicine (IF: 2.43); BMC Cardiovascular Disorders (IF: 2.17); Genetic Testing and Molecular Biomarkers (IF: 1.74); Medicine (IF: 1.55); European Heart Journal - Open; American Journal of Medicine Open; Cardiac Failure Review; European Heart Journal - Case Reports; Cardiology and Therapy; Vascular Health and Risk Management; Advances in Bioscience and Biotechnology.
OTHER ACTIVITIES	▪ Scientific news reporter for “CardioLink Scientific News” (www.cardiolink.it/v2/) - January 2022 to present ▪ University counselling for high school students - 2011 to present
MEMBERSHIPS	▪ European Society of Cardiology (ESC) (Professional Membership) ▪ Heart Failure Association of the ESC (Silver Membership) ▪ HoT (Heart Failure Specialists of Tomorrow) ▪ Società Italiana di Cardiologia (SIC) ▪ Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) ▪ Italian Society of Amyloidosis
AWARDS AND PRIZES	▪ Best clinical presentation. PhD Day 2024 - PhD Programme in Translational Medicine - Scuola Superiore Sant’Anna. Pisa - 16/10/2024. Presentation title: <i>Epidemiology and Pathophysiology of Cardiac Amyloidosis: Insights from Biomarkers</i> ▪ Premio Fausto Rovelli 2024, 58° Convegno Cardiologia Milano. Milan -

	25/09/2024. Abstract title: <i>Incidence and clinical characteristics of cardiac amyloidosis in Tuscany and Umbria</i> ▪ Young researcher award, 2nd place, “Biomarkers of the Future 2022” - 15-16/11/2022. Presentation title: <i>NT-proBNP and High-Sensitivity Troponin T Hold Diagnostic Value in Cardiac Amyloidosis</i> ▪ Young investigator award, Pisa Amyloid 2022. FTGM, Pisa - 30/06/2022 and 01/07/2022 Abstract title: <i>NT-proBNP and High-Sensitivity Troponin T Hold Diagnostic Value in Cardiac Amyloidosis</i> ▪ The most cited paper award, 82nd National Congress of the Italian Society of Cardiology. Rome - 09-12/12/2021 Publication title: <i>Use of biomarkers to diagnose and manage cardiac amyloidosis</i> ▪ Best clinical case, 80th National Congress of the Italian Society of Cardiology. Rome - 12-15/12/2019 Abstract title: <i>A young girl with a “spongy” heart</i> ▪ Admission to Sant’Anna School of Advanced Studies, Class of Medical Sciences, Pisa, Italy - national selection (2011 admission rate: 4% [47/1096]) - October 2011 ▪ First classified (out of 78721 candidates) at national selection to enter Medical School - September 2011
GRANTS	▪ Co-investigator: E-schoolapius: the heart its signs and symptoms. E-learning Cardiology course, first classified at "Talent Italy" award (100,000 €), promoted by the Italian Ministry of Instruction, University and Research for the best Italian MOOC ▪ Co-investigator: A dynamic evaluation of chronic heart failure prognosis: the MECKI score. Project Code: PNRR-MAD-2022-12375794
PI/INVESTIGATOR Clinical trials	▪ Site investigator for the REMOTE-HF trial (Bayer) ▪ Site investigator for the ATTRIBUTE-CM trial and its open-label extension (Eidos Therapeutics) ▪ Site investigator for the CARDIO-TTTransform trial and its extension (Ionis Pharmaceuticals) ▪ Site investigator for the trial “Efficacy and safety of NNC6019-0001 at two dose levels in participants with transthyretin amyloid cardiomyopathy” (Novo Nordisk) ▪ Site investigator for the DepleTTR-CM trial (Alexion Pharmaceuticals) ▪ Site investigator for the MAGNITUDE trial (Intellia Therapeutics)
Multicentric observational studies	▪ Co-PI of the TACTIC study (“Circulating TrAnsthyretin in transthyretin Cardiac amyloidosis: biochemical characTerization and Correlates”) ▪ Site investigator for the study “A dynamic evaluation of chronic heart failure prognosis: the MECKI score” ▪ Site investigator for the BRING-UP Prevenzione and the BRING-UP3 Scompenso studies ▪ Site investigator for the OPTIPHARM-HF registry

CLINICAL TRAINING COURSES AND ACCREDITATIONS	▪ AHA Advanced Cardiovascular Life Support course. FTGM, Pisa - 12/11/2024 ▪ Next Generation ANMCO. Florence - November 2023 to February 2024 ▪ AHA Basic Life Support course. FTGM, Pisa - 26/02/2024 ▪ Test da Sforzo Cardiopolmonare. Centro Cardiologico Monzino, Milan - 20-24/02/2023 ▪ Corso formativo sulla Clinical Trial Unit di Fase 1. FTGM, Pisa - 24/11/2022 ▪ Course “Corso base in materia di radioprotezione dei lavoratori in campo sanitario”. AOUP, Pisa - 23/11/2020 ▪ Course “L’insufficienza respiratoria acuta. Uso della NIV”. Centro di Simulazione Medica AOUP, Pisa - 20/02/2019 ▪ Course “18° corso teorico pratico di ecocardiografia in area critica”. AOUP, Pisa - 13-15/02/2019 ▪ Course “Introduzione alla norma ISO 9001:2015 e procedure gestionali del Centro di Biomedicina Sperimentale”. CNR, Pisa - 20/11/2018 ▪ Course “Il Test da Sforzo Cardiopolmonare (CPET): sempre più uno strumento clinico multidisciplinare”. Centro Cardiologico Monzino, Milan - 07-08/05/2018. ▪ Course “Simulazione alla manualità in area critica”. Centro di Simulazione Medica AOUP, Pisa - 12/05/2016 and 11/06/2016							
PERSONAL SKILLS AND COMPETENCES								
Mother tongue	Italian							
Other languages								
Certificates	CAE grade C (June 2013) (level C-1, Common European Framework of Reference for Languages)							
Self-assessment	Understanding				Speaking		Writing	
	Listening		Reading					
English	Proficient	C-2	Proficient	C-2	Advanced	C-1	Advanced	C-1
Communication skills	Good communication skills.							
Organisational skills	Good organisational/managerial skills, good teamworking skills.							
Computer skills	Proficient in Microsoft Office (Word, Excel, Power Point).							
Research skills	Study design, data acquisition and analysis, statistics (SPSS, NCSS, MedCalc), paper writing.							

Last updated: 07 March 2025

I hereby confirm that the data reported are true (D.P.R. n.445/2000 – "Disposizioni legislative in materia di documentazione amministrativa. (Testo A)") and authorize the treatment of my personal data according to the current Italian and European directives (art. 13 d. lgs. 30 giugno 2003 n° 196 "Codice in materia di protezione dei dati personali" and art. 13 GDPR 679/16 – "Regolamento europeo sulla protezione dei dati personali")